Form 4 for BRTX BioRestorative Therapies, Inc.
Accepted 2021-12-02 00:00:00 ET · period of report 2021-12-01 · accession 0001567619-21-021415 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-02 | 2021-12-01 | BRTX | ALSTODT LANCE | Pres, CEO, COB, Dir | P - Purchase | $5.50 | +799 | 159.6K | +0.5% | +$4,394 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-01 | P | A | 799 | $5.50 | 159,613 | D | — | — | (F1) Includes 146,740 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 48,914 shares on March 18, 2022 and 48,913 shares on each of March 18, 2023 and March 18, 2024. |